Search
forLearn
5 / 801 resultslearn Saccharomyces Ferment
learn Beta glucan
learn Lactobacillus
learn sesbania grandiflora extract
Research
5 / 1000+ resultsresearch Application of Transglutaminase for Hair Revitalization
Transglutaminase can repair damaged hair, making it stronger and shinier.
research Current aspects of the development of science and technology
Science and technology are rapidly advancing and impacting various aspects of life in Ukraine.
research Computer-Aided Designing Peptide Inhibitors of Human Hematopoietic Prostaglandin D2 Synthase Combined Molecular Docking and Molecular Dynamics Simulation
Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
research Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
research In the Absence of Streptomycin, Minoxidil Potentiates the Mitogenic Effects of Fetal Calf Serum, Insulin-Like Growth Factor 1, and Platelet-Derived Growth Factor on NIH 3T3 Fibroblasts in a K + Channel-Dependent Fashion
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Why there are no updates from Amplifica about SCUBE3 & AMP-303?
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.